drug · small molecule
VENCLEXTA
updated 5mo ago/ ve-NE-tə-klaks /
by $ABBV AbbVie Inc.🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 7- drugvenetoclax82 co-mentions · 22 sources
- tagApproval80 co-mentions · 20 sources
- tagSmall Molecule40 co-mentions · 20 sources
- tagOncology2 co-mentions · 2 sources
- tagHematology2 co-mentions · 1 sources
- companyInstitute of Hematology and Blood Diseases Hospital1 co-mentions · 1 sources
- tagAML1 co-mentions · 1 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for chronic lymphocytic leukemia and neoplasm and 38 investigational indications.
targets
Apoptosis regulator Bcl-2
all catalysts(0)
nothing on the calendar yet
Trials studying VENCLEXTA
- phase3A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
- phase1Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
- phase2Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)
- phase2A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period
- phase1A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
- phase3A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- phase1A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
- phase2Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
News(10)
- BMS dumps $100M Orum degrader-antibody conjugate after glimpsing phase 1 dataBristol Myers Squibb has axed the degrader-antibody conjugate it bought from Orum Therapeutics for $100 million, walking away from the asset after seeing phase 1 data.fiercebiotech · 16d ago
- Chutes & Ladders—Legend CEO departs without successor in placeLegend Biotech CEO Ying Huang, Ph.D., has left the company suddenly, without a predecessor in place. Huang was elevated from CFO to CEO in 2020 after a Chinese customs investigation was opened on f…fiercebiotech · 2mo ago
- Sarepta names former AbbVie R&D exec Michael Severino as next CEOAfter leaving Tessera Therapeutics earlier this month, Michael Severino will take over Sarepta Therapeutics as the biotech awaits two key regulatory decisions in Duchenne muscular dystrophy.biospace · 2mo ago
- Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workersHundreds of executives and investors are pushing for Rick Pazdur to be the next FDA commissioner. Elsewhere, Takeda detailed its latest restructuring and Alumis is discarding a once-highly touted i…biopharma_dive · 4mo ago
- BeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at VenclextaBeOne Medicines has clinched an accelerated approval for its drug sonrotoclax in mantle cell lymphoma (MCL), marking the start of its bid to challenge AbbVie and Roche's Venclexta across a range of…endpoints · 4mo ago
- Dr Loghavi on the Significance of Updated WHO Diagnostic Criteria for AML in Clinical PracticeSanam Loghavi, MD, discusses updated WHO diagnostic criteria for acute myeloid leukemia and its significance for diagnoses and treatment selection.onclive · 4mo ago
- FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AMLThe FDA has approved oral decitabine/cedazuridine plus venetoclax for newly diagnosed AML unfit for intensive chemo, based on phase 2 ASCERTAIN-V data.onclive · 4mo ago
- FDA Approves Sonrotoclax for Relapsed/Refractory Mantle Cell LymphomaThe FDA granted accelerated approval to sonrotoclax for relapsed/refractory mantle cell lymphoma after at least 2 lines of systemic therapy.onclive · 4mo ago
- Dr Dinardo on the FDA Approval of Decitabine/Cedazuridine Plus Venetoclax in AMLCourtney D. DiNardo, MD, MSCE, discusses the FDA approval of decitabine/cedazuridine plus venetoclax in acute myeloid leukemia.onclive · 4mo ago
- Combination and Sequencing Strategies in Metastatic Castration-Resistant Prostate CancerDr. Pedro Barata and Dr. Johann De Bono discuss ongoing questions surrounding combination approaches and optimal sequencing strategies for radiopharmaceutical therapies in metastatic castration-res…onclive · 4mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that